Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system

被引:23
|
作者
Zimmerman, Robert S. [1 ]
Hobbs, Todd M. [2 ]
Wells, Brian J. [3 ]
Kong, Sheldon X. [2 ]
Kattan, Michael W. [4 ]
Bouchard, Jon [2 ]
Chagin, Kevin M. [4 ]
Yu, Changhong [4 ]
Sakurada, Brian [2 ]
Milinovich, Alex [4 ]
Weng, Wayne [2 ]
Bauman, Janine M. [4 ]
Pantalone, Kevin M. [1 ]
机构
[1] Cleveland Clin, Endocrinol, Cleveland, OH 44106 USA
[2] Novo Nordisk, Plainsboro, NJ USA
[3] Wake Forest Sch Med, Clin & Translat Sci Inst, Winston Salem, NC USA
[4] Cleveland Clin, Quantitat Hlth Sci, Cleveland, OH 44106 USA
来源
DIABETES OBESITY & METABOLISM | 2017年 / 19卷 / 11期
关键词
glucagon-like peptide-1 receptor agonist; cardiovascular risk; cardiovascular disease; mortality; type-2; diabetes; PROTAMINE HAGEDORN INSULIN; TO-TARGET TRIAL; GLYCEMIC CONTROL; BASAL INSULIN; COMBINATION THERAPY; PLUS METFORMIN; NPH INSULIN; GLARGINE; PREDICTORS; HYPOGLYCEMIA;
D O I
10.1111/dom.12969
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To assess the potential impact of glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure on cardiovascular disease (CVD) and mortality outcomes in patients with type 2 diabetes (T2D), using a large retrospective cohort. Research Design and Methods: Patients who had T2D between 2005 and 2014 (N = 105 862) were identified from the electronic health record system at Cleveland Clinic using a validated electronic phenotype. A time-dependent, Cox, multiple regression analysis was used to assess the association between GLP-1RA exposure and risk of acute myocardial infarction (AMI), stroke/cerebrovascular accident (CVA), and overall mortality, as well as the composite of all three outcomes. The findings were further evaluated by assessing the effect of GLP-1RAs on the same variables in patients with and without prior CVD. The model adjusted for differences in demographic information, hypertension, laboratory/vital signs, history of outcomes, and T2D medications. Results: There were significantly lower rates of AMI (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.65 to 0.99; P =.045), CVA (HR 0.82, 95% CI 0.74 to 0.91, P <.001), overall mortality (HR 0.48, 95% CI 0.41 to 0.57; P <.001), and the composite outcome (HR 0.82, 95% CI 0.74 to 0.91; P <.002) during the consolidated time that patients were exposed to GLP-1RAs compared to corresponding rates during intervals without GLP-1RA exposure. GLP-1RA treatment was associated with a significant decrease in CVA, mortality, and the composite outcome in patients with and without established CVD, not significantly affecting AMI in these subgroups. Conclusions: GLP-1RA exposure was found to be associated with a reduction in the risk of cardiovascular events observed and overall mortality among patients with T2D with and without established CVD, after adjusting for potential confounders.
引用
下载
收藏
页码:1555 / 1561
页数:7
相关论文
共 50 条
  • [21] Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
    Kim, Hyun Jin
    Park, Seok O.
    Ko, Seung-Hyun
    Rhee, Sang Youl
    Hur, Kyu-Yeon
    Kim, Nan-Hee
    Moon, Min Kyong
    Lee, Byung-Wan
    Kim, Jin Hwa
    Choi, Kyung Mook
    DIABETES & METABOLISM JOURNAL, 2017, 41 (06) : 423 - 429
  • [22] Renal Function Improvement With Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Type 2 Diabetes
    Yanai, Hidekatsu
    JOURNAL OF MEDICAL CASES, 2024, 15 (2-3) : 37 - 42
  • [23] Dual metformin and glucagon-like peptide-1 receptor agonist therapy reduces mortality and hepatic complications in cirrhotic patients with diabetes mellitus
    Huynh, Daniel J.
    Renelus, Benjamin D.
    Jamorabo, Daniel S.
    ANNALS OF GASTROENTEROLOGY, 2023, : 555 - 563
  • [24] A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus
    Thondam, S. K.
    Cuthbertson, D. J.
    Aditya, B. S.
    MacFarlane, I. A.
    Wilding, J. P.
    Daousi, C.
    CLINICAL ENDOCRINOLOGY, 2012, 77 (04) : 635 - 637
  • [25] Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use
    Rossing, Peter
    Agarwal, Rajiv
    Anker, Stefan D.
    Filippatos, Gerasimos
    Pitt, Bertram
    Ruilope, Luis M.
    Fonseca, Vivian
    Umpierrez, Guillermo E.
    Caramori, Maria Luiza
    Joseph, Amer
    Lambelet, Marc
    Lawatscheck, Robert
    Bakris, George L.
    DIABETES OBESITY & METABOLISM, 2023, 25 (02): : 407 - 416
  • [26] Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes
    Ng, Elisabeth
    Shaw, Jonathan E.
    Wood, Anna
    Maple-Brown, Louise J.
    Hare, Matthew J. L.
    AUSTRALIAN JOURNAL OF GENERAL PRACTICE, 2022, 51 (07) : 513 - 518
  • [27] HEALTH CARE COSTS AMONG TYPE 2 DIABETES MELLITUS PATIENTS INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1RA) THERAPY
    Johnston, S. S.
    Nguyen, H.
    Felber, E.
    Cappell, K.
    Nelson, J.
    Chu, B. C.
    Kalsekar, I
    VALUE IN HEALTH, 2014, 17 (03) : A244 - A244
  • [28] Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings
    Guerci, B.
    Charbonnel, B.
    Gourdy, P.
    Hadjadj, S.
    Hanaire, H.
    Marre, M.
    Verges, B.
    DIABETES & METABOLISM, 2019, 45 (06) : 528 - 535
  • [29] Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
    Desai, Aakash
    Petrov, Jessica
    Hashash, Jana G.
    Patel, Harsh
    Brahmbhatt, Bhaumik
    Kochhar, Gursimran S.
    Farraye, Francis A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (05) : 620 - 632
  • [30] Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features
    Lyseng-Williamson, Katherine A.
    CLINICAL DRUG INVESTIGATION, 2019, 39 (08) : 805 - 819